S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
Log in

NASDAQ:TRPXTHERAPIX BIOSCI/S Stock Price, Forecast & News

$0.32
0.00 (0.00 %)
(As of 07/16/2020)
Add
Compare
Today's Range
$0.32
Now: $0.32
$0.32
50-Day Range
$0.32
MA: $0.44
$0.76
52-Week Range
$0.25
Now: $0.32
$4.69
VolumeN/A
Average VolumeN/A
Market Capitalization$1.11 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRPX
CUSIPN/A
Phone972-3616-7055

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees9
Market Cap$1.11 million
Next Earnings DateN/A
OptionableNot Optionable
$0.32
0.00 (0.00 %)
(As of 07/16/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive TRPX News and Ratings via Email

Sign-up to receive the latest news and ratings for TRPX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











THERAPIX BIOSCI/S (NASDAQ:TRPX) Frequently Asked Questions

How has THERAPIX BIOSCI/S's stock been impacted by COVID-19 (Coronavirus)?

THERAPIX BIOSCI/S's stock was trading at $0.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TRPX stock has decreased by 29.6% and is now trading at $0.3170.
View which stocks have been most impacted by Coronavirus
.

How were THERAPIX BIOSCI/S's earnings last quarter?

THERAPIX BIOSCI/S (NASDAQ:TRPX) announced its quarterly earnings results on Monday, August, 20th. The company reported ($0.35) EPS for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.24.
View THERAPIX BIOSCI/S's earnings history
.

Has THERAPIX BIOSCI/S been receiving favorable news coverage?

Media stories about TRPX stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. THERAPIX BIOSCI/S earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about THERAPIX BIOSCI/S
.

Who are some of THERAPIX BIOSCI/S's key competitors?

What other stocks do shareholders of THERAPIX BIOSCI/S own?

Who are THERAPIX BIOSCI/S's key executives?

THERAPIX BIOSCI/S's management team includes the following people:
  • Dr. Ascher Shmulewitz, Chairman & Interim CEO (Age 63)
  • Dr. Adi Zuloff-Shani, Chief Technology Officer (Age 51)
  • Mr. Oz Adler CPA, Chief Financial Officer (Age 32)

What is THERAPIX BIOSCI/S's stock symbol?

THERAPIX BIOSCI/S trades on the NASDAQ under the ticker symbol "TRPX."

Who are THERAPIX BIOSCI/S's major shareholders?

THERAPIX BIOSCI/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (1.18%).

Which institutional investors are buying THERAPIX BIOSCI/S stock?

TRPX stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG.

How do I buy shares of THERAPIX BIOSCI/S?

Shares of TRPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is THERAPIX BIOSCI/S's stock price today?

One share of TRPX stock can currently be purchased for approximately $0.32.

How big of a company is THERAPIX BIOSCI/S?

THERAPIX BIOSCI/S has a market capitalization of $1.11 million. THERAPIX BIOSCI/S employs 9 workers across the globe.

What is THERAPIX BIOSCI/S's official website?

The official website for THERAPIX BIOSCI/S is therapixbio.com.

How can I contact THERAPIX BIOSCI/S?

THERAPIX BIOSCI/S's mailing address is 4 ARIEL SHARON STREET HASHAHAR TOWER 16TH FLOOR, GIVATAYIM L3, 5320047. The company can be reached via phone at 972-3616-7055 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.